The FDA has granted breakthrough device designation to Abiomed’s Impella ECP expandable percutaneous heart pump. Impella ECP is the smallest heart pump in the world and the first to be compatible with small bore access and closure techniques. https://t.co/ftI3xIfP4b
We’re looking for a structural heart fellow for 2022-2023 in Portland! High volume, great cases, clinical trials, very hands-on. DM or email me. #TAVR#MitraClip@brandonjonesmd@EricKirker@Regadenoson @AshwatDhillon
Glad to see surgeons adopting the 5.5. When we get a 5L device that is percutaneously delivered through a <16F sheath, AMICS will have a mortality rate <10%!!!
In the SYNTAX trial, anatomic complete revasc (CR) was more common after CABG than PCI. Compared with CABG+CR, PCI+CR had lower 10-year mortality. Conversely mortality was higher after PCI with incomplete revasc. Must honestly appraise likelihood of CR after PCI when choosing.
A protocol involving early use of invasive hemodynamics and mechanical circulatory support conferred a survival benefit in patients with acute MI and cardiogenic shock @SCAI#SCAI2021#CardioNews#CardioTwitter https://t.co/dFuVv8V6HT
💪> 70% survival in AMI-CS👍: really really impressive results (and the result of years of research and hard work conceived, implemented, and led by @Babar_Basir@BillONeillMD@Mike_Hacala and others)👏... @SCAI